Compare ADMA Biologics Inc (ADMA) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Bank of New York Mellon Corp — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Bank of New York Mellon Corp trades at $159.91 (market cap $108.78B). The key difference: Bank of New York Mellon Corp is far larger — about 49× ADMA Biologics Inc's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BNY | |
|---|---|---|
Market Cap | $2.22B | $108.78B |
Sector | Health | Financials |
52-Week High | $20.38 | $162.35 |
52-Week Low | $7.60 | $101.00 |
Enterprise Value | $2.29B | — |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
